Title	Follicular dendritic cell sarcoma of small intestine with aberrant T-cell marker expression
Author(s)	Yamada, Yosuke; Haga, Hironori; Hernandez, Mako; Kubota, Kanako C.; Orii, Fumika; Nagashima, Kazuo; Matsuno, Yoshihiro
Citation	Pathology International, 59(11), 809-812 https://doi.org/10.1111/j.1440-1827.2009.02449.x
Issue Date	2009-11
Doc URL	http://hdl.handle.net/2115/44110
Rights	The definitive version is available at www.blackwell-synergy.com
Type	article (author version)
File Information	PI59-11_809-812.pdf

[Instructions for use](#)

<Title page>

[The title]

Follicular dendritic cell sarcoma of small intestine with aberrant T-cell marker expression.

[Short running title]

FDC sarcoma with T-cell marker (26 letters)

[The full names of the authors]

Yosuke Yamada ¹, Hironori Haga ¹, Mako Hernandez ¹, Kanako Kubota ¹, Fumika Orii ², Kazuo Nagashima³ and Yoshihiro Matsuno ¹.

[Corresponding author]

Yoshihiro Matsuno, MD, PhD.

Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Japan, 1 Nishi 5 chome, kita 14 jo, Kita-ku, Sapporo 060-8648, Japan.

Tel: 011-706-5716, Fax: 011-707-5116.

E-mail: ymatsuno@med.hokudai.ac.jp.

[The address of the institutions etc]

1 Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Japan

Departments of 2 Internal Medicine and 3 Surgical Pathology, Sapporo Higashi Tokushukai Hospital, Sapporo, Japan

<Abstract> (no more than 200 words)

Follicular dendritic cell sarcoma (FDCS) is an uncommon neoplasia usually occurring in lymphoid tissue. Herein we present a case of FDCS of the small intestine with positivity for T-cell antigen, simulating T-cell lymphoma. An 82-year-old man consulted a doctor for epigastric pain of one-week duration. Imaging study revealed a mass in the small intestine. Malignant lymphoma was suspected because of high serum levels of soluble interleukin-2 receptor, and resection of the tumor was performed. Microscopically, the tumor was comprised of large pleomorphic cells with reactive small lymphocytes. Most of the nuclei of the tumor cells were round or ovoid-shaped, and some of the tumor cells also showed spindle-shaped nuclei. Although the tumor cells were diffusely positive for CD45RO and CD4 immunohistochemically, negativity for pan-T-cell markers and CD56 were unusual for T-cell lymphoma of intestinal origin. Additional immunohistochemical study demonstrated that the tumor cells were positive for follicular dendritic cell markers including CD23, CD35 and CAN.42, and diagnosis of FDCS was made. To our knowledge, this is the first case of FDCS aberrantly expressing CD45RO, and FDCS expressing T-cell markers can be a pitfall for diagnosis of FDCS. (190 words)

<Key words>

Dendritic cell sarcoma, follicular

Intestine, small

Lymphoma, T-cell

<Text>

[Introduction]

Follicular dendritic cell sarcoma (FDCS) is a tumor composed of spindle or oval cells with follicular dendritic cell differentiation. Usually, their morphology and immunohistochemical features are distinct from those of non-Hodgkin lymphomas. In this report, we present FDCS in an elderly man with pleomorphic histology and T-cell marker expression, simulating T-cell lymphoma.

[Clinical summary]

The patient was a previously healthy 82-year-old Japanese man. He visited a hospital for epigastric pain of one-week duration. Physical examination revealed a firm mass in the upper part of the abdomen. Abdominal CT scan showed focal obstruction of the small intestine by thickening of the intestinal wall. Contrast enema using an ileus pipe demonstrated severe stenosis at 50 cm distal to the Treitz ligament. The serum level of soluble interleukin-2 receptor was elevated to 1470 U/ml (normal range, 145-519 U/ml). A malignant lymphoma of small intestine was suspected, and partial resection of the jejunum was performed. After the operation, he was received adjuvant chemotherapy (CHOP) for 3 months and there was no evidence of recurrence at 12-month follow-up.

[Pathological findings]

Macroscopically, a mass measuring 10 x 10 cm in greatest dimension was seen in the jejunum extending throughout the wall of the intestine. Cut surface demonstrated a well-circumscribed, gray-white solid tissue with focal hemorrhage (Figure 1).

Microscopically, the tumor consisted of large pleomorphic cells, mainly forming diffuse sheets. Focal coagulative necrosis was found (Figure 2). The large cells had faintly eosinophilic cytoplasm and pleomorphic nuclei with coarse chromatin and distinct nucleoli. Nuclear pseudo-inclusion, binucleated and multinucleated nuclei were also present. Mitotic figures

were numerous (50 counts / 10 high power field) (Figure 3). In the background of the tumor cells, interspersed small lymphocytes were evident, and some of them were seen around the blood vessels. Lymphoid follicles were recognizable in some areas of the tumor. Regional lymph node involvement of the tumor with sparing of some lymph follicles was also noted.

The results of immunohistochemistry are summarized in Table 1. The tumor cells were focally (5%) positive for pan-B-cell marker CD20, and diffusely positive for CD45RO (Figure 4), a T-cell marker, as well as CD45RB. But the tumor cells did not show positivity for pan T-cell markers including CD3 and CD5. The tumor cells were diffusely positive for CD4 (Figure 4), CD68, and vimentin, and showed immunoreactivity for follicular dendritic cell markers including CD23, CD35, and CNA.42 (Figure 5). They were focally positive for S-100 protein and negative for CD21 (Figure 5) and D2-40. Ki-67 index was 90%.

In situ hybridization for Epstein-Barr virus encodes small RNA (EBER) { INFORM EBER probe (CE) (Roche)} failed to show positive cells. In clonal analysis, genomic DNA was extracted from paraffin-embedded tissue and T-cell receptor (TCR) γ gene rearrangements were studied by PCR. The amplified DNA yielded a polyclonal smear pattern on electrophoresis.

A final diagnosis of FDCL was made on these findings.

[Discussion]

FDCL is a neoplasm consisting of spindle to ovoid cells, which closely mimics various types of tumors and tumor-like lesions. Typically, they are nodal in origin, but extranodal involvement including the small intestine has been reported¹. In case of intestinal FDCL, the major differential diagnosis includes gastrointestinal stromal tumor (GIST) and primary intestinal lymphomas. In this case, GIST was easily excluded by a lack of expression of CD34 and c-kit in the tumor cells. Expression of T-cell markers, including CD4 and CD45RO, however, might have lead to a diagnosis of T-cell lymphoma of intestinal origin. Enteropathy-type T-cell lymphomas among Japanese are type 2 in most cases, and are phenotypically characterized by positivity of CD8 and CD56². Peripheral T-cell lymphoma, not otherwise specified, often

demonstrates CD4 with frequent loss of CD5 or CD7. However, complete loss of pan-T-cell markers is unusual for T-cell lymphoma. In our case, the possibility of aberrant expression of T-cell antigens in a non-lymphoid tumor was considered. Infiltration of small lymphocytes, especially around the blood vessels, suggested the possibility of FDCS³.

For investigation of undifferentiated neoplasm, including FDCS in the differential diagnosis is important since follicular dendritic cell markers are usually not included in the first panel of antibodies. To diagnose FDCS, at least one FDC marker (CD21, CD35, CD23, KiM4p and CNA.42) should be positive and CD1a should be negative³. For lymphoid markers, CD20 and CD45(LCA) have been reported to be occasionally positive, while CD3, a pan-T-cell marker, is consistently negative³. Our case suggests that even some T-cell associated antigens can be demonstrated in FDCS.

Although CD4 is a co-receptor acting in the activation of T-helper cells by the MHC class II antigen restricted pathway, CD4 expression is not restricted to T lymphocytes. Langerhans' cells, plasmacytoid dendritic cells/monocytes and true histiocytic sarcomas are known to be positive for CD4^{4,5}. Likewise, CD45RO, recognized by antibody UCHL-1 and once widely used as a T-cell marker on paraffin sections⁶, can be expressed in histiocytic tumors⁷. Actually, both CD4 and CD45RO lack lineage specificity and are commonly expressed by histiocytic sarcoma⁸. Additionally, our case expressed CD68, one of the most available histiocytic markers. For diagnosis of histiocytic sarcoma, however, dendritic cell markers should be negative and other histiocyte-specific markers such as lysozyme or CD163 are usually expressed. In this case, the tumor cells were negative for CD68, and CD163 was not available. Differential diagnosis from the CD4+ blastic plasmacytoid dendritic cell neoplasm would be straight forward, because of non-hematodermic distribution, more sarcomatous morphology, and negativity for immunoreactive CD56 in this case.

Chan et al. reported that mitotic rate of FDCS is usually between 0 and 10/10HPF and Ki-67 labeling index are between 1 and 25% (mean 13%)³. In contrast, our case showed high proliferative index (mitotic rate of 50/10 high power fields and Ki-67 labeling index of 90%). As poor prognostic factors of FDCS, significant cytologic atypia, extensive

coagulative necrosis, a high proliferative index, large tumor size (> 6cm) or intraabdominal location are documented³ , and our case meets the all factors. Moreover, to the best of our knowledge, there have been 7 reported cases of primary gastrointestinal FD^{CS}⁹⁻¹⁵, and 6 among the 7 showed recurrence and/or metastasis. In our case, regional lymph node metastasis is found. Considering those findings, we think that our case is a high-grade malignancy, and that careful follow-up is needed.

In summary, we present a case of FD^{CS} of small intestine origin. Expression of CD45RO was a feature that has not been previously reported. Including follicular dendritic cell markers into immunohistochemical panel and awareness of key histologic features such as perivascular distribution of small lymphocytes and residual lymphoid follicles in the tumor were crucial for diagnosis of FD^{CS}. Possibility of FD^{CS} with unusual phenotypic expression should be considered in undifferentiated neoplasms with a mixed population of lymphocytes.

<References>

- 1) Kevin H, Gordon S, Ioanna Z et al. Extranodal follicular dendritic cell sarcoma of the gastrointestinal tract: morphologic, immunohistochemical and ultrastructural analysis of two cases. *Hematopathology* 1994;103:90-97.
- 2) Akiyama T, Okino T, Konishi H et al. CD8+, CD56+(natural killer-like) T-cell lymphoma involving the small intestine with no evidence of enteropathy: clinicopathology and molecular study of five Japanese patients. *Pathol Int.* 2008;58:626-34.
- 3) JKC Chan, SA Pileri, G Delsol et al. Follicular dendritic cell sarcoma. In: SH Swerdlow, E Campo, NL Harris, ES Jaffe, SA Pileri, H Stein et al, editors. *WHO classification of tumours of haematopoietic and lymphoid tissues*. Switzerland: IARC;2008.p.363-364.
- 4) Pileri SA, Grogan TM, Harris NL et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. *Histopathology* 2002;41:1-29.
- 5) Herling M, Jones D. CD4+/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells. *Am J Clin Pathol* 2007; 127:687-700
- 6) Steward M, Bishop R, Piggott NH et al. Production and characterization of a new monoclonal antibody effective in recognizing the CD3 T-cell associated antigen in formalin-fixed embedded tissue. *Histopathology* 1997;30:16-22.
- 7) Zhang X, Kryston JJ, Michalak WA, et al. Histiocytic sarcoma in the small intestine: a case report with flow cytometry study and review of the literature. *Pathol Res Pract* 2008;204:763-70. Epub 2008 Jun 9.
- 8) Sun W, Nordberg ML, Fowler MR. Histiocytic sarcoma involving the central nervous system: clinical, immunohistochemical, and molecular genetic studies of a case with review of the literature. *Am J Surg Pathol* 2003;27:258-65.
- 9) Hollowood K, Stamp G, Zouvani I, et al. Extranodal follicular dendritic cell sarcoma of the gastrointestinal tract. Morphologic, immunohistochemical and ultrastructural analysis of two cases. *Am J Clin Pathol* 1995;103:90-7.

- 10) Han JH, Kim SH, Noh SH et al. Follicular dendritic cell sarcoma presenting as a submucosal tumor of the stomach. *Arch Pathol Lab Med* 2000;124:1693-6.
- 11) Chang KC. Follicular dendritic cell sarcoma of the colon mimicking stromal tumour. *Histopathology* 2001;38:25-29.
- 12) Geerts A, Lagae E, Dhaene K et al. Metastatic follicular dendritic cell sarcoma of the stomach: a case report and review of the literature. *Acta Gastroenterol Belg* 2004;67:223-7.
- 13) D O' Mally. Diagnosis: follicular dendritic cell tumor mimicking GI stromal tumor. <http://socforheme.org/case-non-04.htm>.
- 14) Shia J. Extranodal follicular dendritic cell sarcoma: clinical, pathologic, and histogenetic characteristics of an underrecognized disease entity. *Virchows Arch* 2006;449:148-158.
- 15) Yang GC, Wang J, Yee HT. Interwoven dendritic processes of follicular dendritic cell sarcoma demonstrated on ultrafast papanicolaou-stained smears: a case report. *Acta Cytol* 2006;50:534-8.

<Figure legends>

Figure 1: The cut surface of the tumor demonstrating a clear border and spreading throughout the wall of the small intestine.

Figure 2: Diffuse proliferation of the tumor cells with focal necrosis. HE section, original magnification x10.

Figure 3: Tumor cells showing abundant faint eosinophilic cytoplasm and pleomorphic nuclei. Occasional mitotic figures are seen. HE section, original magnification x40.

Figure 4: The neoplastic cells are diffusely positive for CD45RO and CD4, original magnification x80

Figure 5: The neoplastic cells are positive for CD23, CD35 and FDC, and negative for CD21, original magnification x20.

Table 1 Immunohistochemistry

Antigen	Clone		Source	Dilution	Results
α SMA	1A4	DAKO	Glostrup, Denmark	1:1000	(-)
Antichymotrypsin	Polyclonal	Zymed	Carlsbad, California, USA	1:100	(-)
Anaplastic lymphoma kinase-1	ALK-1	DAKO	Glostrup, Denmark	1:50	(-)
CD1a	O10	DAKO	Glostrup, Denmark	1:10	(-)
CD3	2GV6	VENTANA	Yokohama, Japan	Prediluted	(-)
CD4	1F6	Novocastra	Newcastle Upon Tyne, UK	1:15	(++)
CD5	4C7	Novocastra	Newcastle Upon Tyne, UK	1:50	(-)
CD8	4B11	Novocastra	Newcastle Upon Tyne, UK	1:40	(-)
CD20	L26	DAKO	Glostrup, Denmark	1:200	(+)
CD21	2G9	Novocastra	Newcastle Upon Tyne, UK	1:50	(-)
CD23	1B12	Novocastra	Newcastle Upon Tyne, UK	1:20	(++)
CD30	Ber-H2	DAKO	Glostrup, Denmark	1:20	(-)
CD34	NU-4A1	NICHIREI	Tokyo, Japan	1:50	(-)
CD35	RLB25	Novocastra	Newcastle Upon Tyne, UK	1:40	(++)
CD45RB	2B11+PD7/26	DAKO	Glostrup, Denmark	1:100	(++)
CD45RO	UCHL-1	DAKO	Glostrup, Denmark	1:200	(++)
CD56	123C3	Zymed	Carlsbad, California, USA	Prediluted	(-)
CD68	PGM-1	DAKO	Glostrup, Denmark	1:100	(++)
C-kit	Polyclonal	DAKO	Glostrup, Denmark	1:400	(-)
Pan-cytokeratin	AE1/AE3	DAKO	Glostrup, Denmark	1:70	(-)
D2-40	D2-40	DAKO	Glostrup, Denmark	1:50	(-)
Follicular dendritic cell	CNA42	DAKO	Glostrup, Denmark	1:50	(++)
Granzyme B	GrB-7	MONOSAN	Uden, Netherlands	1:25	(-)
Ki-67	MIB-1	DAKO	Glostrup, Denmark	1:20	(++: 90%)
Lysozyme	Polyclonal	NICHIREI	Tokyo, Japan	Prediluted	(-)
Myeloperoxidase	Polyclonal	DAKO	Glostrup, Denmark	1:10000	(-)
S-100 protein	Polyclonal	DAKO	Glostrup, Denmark	1:3000	(+)
TIA-1	26gA10F5	IMMUNOTECH	Marseille, France	1:200	(-)
Vimentin	V9	DAKO	Glostrup, Denmark	1:200	(++)

(++), diffusely (5% or more) positive; (+), focally (< 5%) positive; (-), completely negative.

CD45RO

CD4